BridgeMD
New treatment option for Metastatic Castration-resistant Prostate Neoplasms
Official title A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
ClinicalTrials.gov ID: NCT05818683
What this study is testing
What is Pasritamig?
Pasritamig is an investigational medicine, being studied as a potential treatment for metastatic castration-resistant prostate neoplasms.
Also referred to as JNJ-78278343.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazitaxel, docetaxel): Metastatic castration-resistant prostate cancer...
- Measurable or evaluable disease, except for Part 2H
- (a) Part 1A (cetrelimab) - Prior treatment for mCRPC with at least 1 prior androgen receptor pathway inhibitors (ARPI) (that is, abiraterone acetate...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ functions
You likely can't join if
- Active autoimmune disease within the 12 months prior to signing consent that requires systemic immunosuppressive medications
- Toxicity related to prior anticancer therapy that has not returned to Grade less than or equal to (\<=) 1 or baseline levels (except for alopecia...
- Solid organ or bone marrow transplantation
- Known allergies, or intolerance to any of the components (example, excipients) of pasritamig, cetrelimab (Part 1A), cabazitaxel, Part 1B and 2B...
- Significant infections or serious lung, heart or other medical conditions
The study team makes the final eligibility decision.
Where it's taking place
- Sarasota, Florida, United States
- Grand Rapids, Michigan, United States
- St Louis, Missouri, United States
- Brooklyn, New York, United States
- Mineola, New York, United States
- New York, New York, United States
- Philadelphia, Pennsylvania, United States
- Kurralta Park, Australia
- Macquarie University, Australia
- Melbourne, Australia
- Woolloongabba, Australia
- Barcelona, Spain
- Madrid, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sarasota, Florida, United States; Grand Rapids, Michigan, United States; St Louis, Missouri, United States; Brooklyn, New York, United States; Mineola, New York, United States; New York, New York, United States and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.